| PharmGKB | PA161615688 |
| Name | CYP2C19: -3402C>T |
| Annotation | This promoter variant is part of CYP2C19*17 haplotype, which causes increased acitivity and increased transcription of CYP2C19. Patients carrying this allele may exhibit a lack of response to commonly prescribed dosages of certain proton pump inhibitors (PPIs) and antidepressants, due to ultrarapid clearance of these drugs. CYP2C19*17 carriers are more likely to benifit from tamoxifen treatment. |
| Gene | CYP2C19 |
| Featue | |
| Evidence | PubMed ID:16413245; PubMed ID:17625515; PubMed ID:18294333 |
| Drugs | amitriptyline, citalopram, clomipramine, escitalopram, omeprazole, proguanil, tamoxifen |
| Diseases | |
| Curation Level | Curated |
